PT910563E - Antagonistas de receptores de integrina - Google Patents

Antagonistas de receptores de integrina

Info

Publication number
PT910563E
PT910563E PT96923553T PT96923553T PT910563E PT 910563 E PT910563 E PT 910563E PT 96923553 T PT96923553 T PT 96923553T PT 96923553 T PT96923553 T PT 96923553T PT 910563 E PT910563 E PT 910563E
Authority
PT
Portugal
Prior art keywords
alkyl
cycloalkyl
het
cor
opt
Prior art date
Application number
PT96923553T
Other languages
English (en)
Portuguese (pt)
Inventor
William H Miller
William E Bondinell
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PT910563E publication Critical patent/PT910563E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
PT96923553T 1995-06-29 1996-06-28 Antagonistas de receptores de integrina PT910563E (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US66595P 1995-06-29 1995-06-29
US278895P 1995-08-25 1995-08-25
NZ299914A NZ299914A (en) 1995-06-29 1996-12-10 Tricyclic integrin receptor antagonists, preparation and pharmaceutical compositions thereof
HU9603432A HU226056B1 (en) 1995-06-29 1996-12-12 Acetic acid derivatives with dibenzo[a,d]cycloheptene and dibenz[b,e]azepine skeleton, process for their preparation and pharmaceutical compositions containing them
CA002192764A CA2192764C (en) 1995-06-29 1996-12-12 Integrin receptor antagonists
AU75461/96A AU736487B2 (en) 1995-06-29 1996-12-19 Integrin receptor antagonists
NO965607A NO307337B1 (no) 1995-06-29 1996-12-27 Integrin-reseptor-antagonister, anvendelse derav og farmasøytiske preparater inneholdende slike
BR9606200A BR9606200A (pt) 1995-06-29 1996-12-27 Antagonistas de receptor de integrina

Publications (1)

Publication Number Publication Date
PT910563E true PT910563E (pt) 2003-09-30

Family

ID=89994543

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96923553T PT910563E (pt) 1995-06-29 1996-06-28 Antagonistas de receptores de integrina

Country Status (16)

Country Link
EP (1) EP0910563B1 (de)
JP (1) JP3960482B2 (de)
AT (1) ATE238996T1 (de)
AU (1) AU736487B2 (de)
BR (1) BR9606200A (de)
CA (1) CA2192764C (de)
CZ (1) CZ292925B6 (de)
DE (1) DE69627899T2 (de)
DK (1) DK0910563T3 (de)
ES (1) ES2197950T3 (de)
HU (1) HU226056B1 (de)
NO (1) NO307337B1 (de)
NZ (1) NZ299914A (de)
PT (1) PT910563E (de)
SI (1) SI0910563T1 (de)
WO (1) WO1997001540A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
AU8689798A (en) * 1997-08-04 1999-02-22 Smithkline Beecham Corporation Integrin receptor antagonists
EP1027337A4 (de) * 1997-09-04 2002-04-03 Smithkline Beecham Corp Integrin-rezeptor-antagonisten
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1999031061A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
KR20010042587A (ko) 1998-04-09 2001-05-25 기따자또 이찌로 인테그린 알파브이베타3 길항제로서 아미노피페리딘 유도체
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
EP1150965A4 (de) 1999-02-03 2002-05-15 Merck & Co Inc Benzazepin derivate als alpha-v intgrin rezeptor antagonisten
JP2002537260A (ja) * 1999-02-17 2002-11-05 メルク エンド カムパニー インコーポレーテッド αVインテグリン受容体拮抗薬としてのジベンゾ−アゼピン誘導体
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
EP1198231A1 (de) 1999-07-21 2002-04-24 American Home Products Corporation Bicyklischer antagonist selektiv für (alpha)v (beta)3 integrin
EP1209152A4 (de) 1999-08-05 2003-03-12 Meiji Seika Kaisha Omega-amino-alpha-hydroxy-carbonsäure-derivate mit einem integrin alpha v beta antagonismus
EP1208101A4 (de) * 1999-08-06 2003-03-19 Smithkline Beecham Corp Zur behandlung von schlaganfällen nützliche vitronektin-rezeptor-antagonisten
DE19936780A1 (de) * 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10039998A1 (de) * 2000-08-11 2002-02-21 Basf Ag Neue substituierte Diareno-azepin-Derivate als Integrin Liganden
US20020035104A1 (en) 2000-08-18 2002-03-21 Genentech, Inc. Integrin receptor inhibitors
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
EP2445534A2 (de) 2009-05-25 2012-05-02 Merck Patent GmbH Kontinuierliche verabreichung von cilengitid in der krebstherapie
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3972936A (en) * 1974-02-01 1976-08-03 Merck & Co., Inc. 10,11-Dihydro-5-(3-amino-propyl-or-propylidene)-10,10,11,11-tetra-fluoro-5H-dibenzo[a,d]cycloheptenes and-5-ols
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds

Also Published As

Publication number Publication date
EP0910563B1 (de) 2003-05-02
JP3960482B2 (ja) 2007-08-15
NO965607L (no) 1998-06-29
HUP9603432A3 (en) 1999-05-28
JPH11508887A (ja) 1999-08-03
NO965607D0 (no) 1996-12-27
DE69627899T2 (de) 2004-05-19
EP0910563A4 (de) 1999-04-28
CZ292925B6 (cs) 2004-01-14
HUP9603432A2 (hu) 1998-09-28
ATE238996T1 (de) 2003-05-15
EP0910563A1 (de) 1999-04-28
CA2192764C (en) 2008-03-11
CA2192764A1 (en) 1998-06-12
DK0910563T3 (da) 2003-09-01
HK1019594A1 (en) 2000-02-18
AU736487B2 (en) 2001-07-26
CZ367996A3 (cs) 1998-08-12
BR9606200A (pt) 1998-11-03
NO307337B1 (no) 2000-03-20
ES2197950T3 (es) 2004-01-16
HU226056B1 (en) 2008-04-28
AU7546196A (en) 1998-06-25
WO1997001540A1 (en) 1997-01-16
SI0910563T1 (en) 2003-10-31
HU9603432D0 (en) 1997-01-28
NZ299914A (en) 1998-04-27
DE69627899D1 (de) 2003-06-05

Similar Documents

Publication Publication Date Title
BR9606200A (pt) Antagonistas de receptor de integrina
MY131569A (en) 1,5-benzodiazepine derivatives having cck and/or gastrin antagonistic activity
HUP9903769A2 (hu) Vitronektin receptor antagonisták
DE69330959D1 (de) Benzodiazepinderivate
DE69528257D1 (de) KONDENSIERTE HETEROCYCLISCHE VERBINDUNG, DEREN HERSTELLUNG UND VERWENDUNG ALS GnRH ANTAGONISTEN
IL135924A0 (en) Urea derivatives and their use as integrin inhibitors
DK1371645T3 (da) Anvendelse af (3S,2'R)-glycopyrronium som lægemiddel
EE04282B1 (et) Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon
HU9501622D0 (en) 1,4-benzodiazepine derivatives and their use as cck-mudulators
DE69232986D1 (de) TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
IL119828A0 (en) Substituted triazine derivatives their preparation and use
EP0689541A1 (de) Pterinderivate und seine anwendung zur herstellung von immunotestverfahren
DK0688771T3 (da) Anvendelse af lactamforbindelser som farmaceutiske aktivstoffer
ATE166648T1 (de) Benzoxazinderivate, deren herstellung und deren verwendung in therapie
IL116526A0 (en) Piperazinediones their preparation and use
CA2101952A1 (en) Sulfonylurea derivatives, their preparation and their use
DE602004007181D1 (de) 2,4,6-tris(4'aminobenzaldineopentylmalonat)-s-triazin, dieser enthaltenden Sonnenschutzzusammensetzungen und dessen Verwendungen
DK0625982T3 (da) 4-Oxo- og 4H-imidazo(5,1-c)(1,4)benzoxaziner anvendelige som benzodiazepinreceptor-bindemidler
SI0946264T1 (de)
ES2070500T3 (es) Inhibidores de la enzima convertidora de la angiotensina.
PL312329A1 (en) Derivatives of arylothioalkyl thiopyridine
IT1282950B1 (it) Derivati eterociclo-condensati di morfinoidi
Whitaker et al. TENNET IV: Theoretical and Experimental Neuropsychology-Neuropsychologie Expbrimentale et Thborique
HUP0001536A2 (hu) Szulfonamid- és karboxamidszármazékok és hatóanyagként ezeket tartalmazó gyógyszerek
HUP9902914A3 (en) Substituted 6,6-heterobicyclic derivatives as corticotropin releasing factor (hormone) crf (crh) antogonists and use thereof